Appendix 4D & Financial Report - Dec 2016
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Appendix 4C - Quarterly Report & Company Update
- PharmAust Receives $406K R&D Rebate from ATO
- Phase II Strategy Update
- Phase II Canine Trial begins at University of Cambridge
- Epichem achieves ISO 9001 2015 certification
Later from Neurizon Therapeutics
- Dr Richard Hopkins Appointed as CEO of PharmAust
- Appendix 4C - Quarterly Report & Company Update - March 2017
- PharmAust secures core China patent
- New patent granted for non-cancer applications
- Phase II trial prelim results demonstrate clinical benefit
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics